Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: INCRELEX

« Back to Dashboard
Increlex is a drug marketed by Ipsen Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

The generic ingredient in INCRELEX is mecasermin recombinant. One supplier is listed for this compound. Additional details are available on the mecasermin recombinant profile page.

Summary for Tradename: INCRELEX

Suppliers: see list1

Clinical Trials for: INCRELEX

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
Status: Active, not recruiting Condition: Primary Insulin-like Growth Factor-1 Deficiency

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-like Growth Factor-1 Deficiency

Effect of Increlex® on Children With Crohn Disease
Status: Recruiting Condition: Crohn Disease

European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry
Status: Recruiting Condition: IGF1 Deficiency

Long-Term Treatment With rhIGF-1 in GHIS
Status: Active, not recruiting Condition: Growth Hormone Insensitivity Syndrome

Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Status: Completed Condition: Rett Syndrome

Increlex Treatment of Children With Chronic Liver Disease and Short Stature
Status: Not yet recruiting Condition: Growth Failure; Chronic Liver Disease

Treatment of Rett Syndrome With Recombinant Human IGF-1
Status: Recruiting Condition: Rett Syndrome

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-Like Growth Factor-1 Deficiency; Growth Disorders

Metabolic Effects of Growth Hormone (GH) and Insulin-like Growth Factor-I (IGF-I)in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)
Status: Recruiting Condition: Diabetes

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005RXYes5,824,642<disabled><disabled>
Ipsen Inc
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005RXYes5,681,814<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn